Gilead Sciences IncGILD:NSQ

2.220 / 2.76 %
34.52 %
Close in USDToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Jun 27 2016 11:50 BST.

Consensus recommendation

As of Jun 24, 2016, the consensus forecast amongst 25 polled investment analysts covering Gilead Sciences, Inc. advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Oct 21, 2009. The previous consensus forecast advised investors to purchase equity in Gilead Sciences, Inc..

Previous recommendations
Last year3 months ago2 months ago4 weeks agoLatest
Mouseover chart recommendation details.
Latest recommendation
No opinion0

Research Reports

S&P Capital IQ – STARS Reports
Ford Investor Services, Inc.

Share price forecast

The 20 analysts offering 12 month price targets for Gilead Sciences, Inc. have a median target of 115.00, with a high estimate of 135.00 and a low estimate of 81.00. The median estimate represents a 46.96% increase from the last price of 78.25. View Full Financials

High+72.5 %135.00
Med+47.0 %115.00
Low+3.5 %81.00


In 2015, Gilead Sciences Inc reported a dividend of 1.29 USD. The 12 analysts covering the company expect dividends of 1.86 USD for the upcoming fiscal year, an increase of 44.11%. View Full Financials

Div growth (TTM)--
  • Mouseover chart for details.
  • Dividend forecast
  • Quarter 1
  • Quarter 2
  • Quarter 3
  • Quarter 4

Earnings history & estimates

On Apr 28, 2016, Gilead Sciences, Inc. reported 1st quarter 2016 earnings of 3.03 per share. This result was in line with the consensus of the 22 analysts following the company and exceeded last year's 1st quarter results by 3.06%.
The next earnings announcement is expected on Jul 26, 2016. View Full Interim Financials

Average growth rate+0.93 %

Gilead Sciences, Inc. reported annual 2015 earnings of 12.61 per share on Feb 02, 2016. View Full Annual Financials

Average growth rate+89.52 %
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement


Gilead Sciences Inc. had 1st quarter 2016 revenues of 7.79bn. This missed the 8.12bn consensus estimate of the 18 analysts following the company. This was 2.63% above the prior year's 1st quarter results. View Full Interim Financials

Average growth rate+0.84 %

Gilead Sciences Inc. had revenues for the full year 2015 of 32.64bn. This was 31.13% above the prior year's results. View Full Annual Financials

Average growth rate+46.12 %
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement
© Thomson Reuters Click for restrictions.

All markets data located on is subject to the FT Terms & Conditions.

All content on is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.